By ROBERT CYRAN
The premium and increased cash may help bring Allergan to the negotiating table. But questions over Valeant’s own stock remain its weakness, says Robert Cyran of Reuters Breakingviews.
Published: June 2, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1p1qwEZ
via IFTTT
from WordPress http://ift.tt/1h0ssgF
No comments:
Post a Comment